

ACYCLOVIR OINT (CCHP2017)

Products Affected

Step 2:

- *acyclovir 5 % topical ointment*

Details

Criteria	Step Therapy requires trial of one (1) of the following: oral generic acyclovir, oral generic famciclovir, oral generic valacyclovir.
-----------------	---

ALPHAGAN (CCHP2017)

Products Affected

Step 2:

- ALPHAGAN P 0.1 % EYE DROPS

Details

Criteria	
	Step Therapy requires trial of brimonidine 0.15%.

ANTIDEPRESSANT_NVT 2017

Products Affected

Step 2:

- DESVENLAFAXINE ER 100 MG TABLET,EXTENDED RELEASE 24 HR
- DESVENLAFAXINE ER 50 MG TABLET,EXTENDED RELEASE 24 HR
- DESVENLAFAXINE FUMARATE ER 100 MG TABLET, EXTENDED RELEASE 24 HR
- DESVENLAFAXINE FUMARATE ER 50 MG TABLET, EXTENDED RELEASE 24 HR
- *duloxetine 40 mg capsule, delayed release*
- EMSAM 12 MG/24 HR TRANSDERMAL 24 HOUR PATCH
- EMSAM 6 MG/24 HR TRANSDERMAL 24 HOUR PATCH
- EMSAM 9 MG/24 HR TRANSDERMAL 24 HOUR PATCH
- FETZIMA 120 MG CAPSULE,EXTENDED RELEASE
- FETZIMA 20 MG (2)-40 MG (26) CAPSULE,EXTENDED RELEASE,24 HR,DOSE PACK
- FETZIMA 20 MG CAPSULE,EXTENDED RELEASE
- FETZIMA 40 MG CAPSULE,EXTENDED RELEASE
- FETZIMA 80 MG CAPSULE,EXTENDED RELEASE
- *fluvoxamine er 100 mg capsule, extended release 24 hr*
- *fluvoxamine er 150 mg capsule, extended release 24 hr*
- MARPLAN 10 MG TABLET
- TRINTELLIX 10 MG TABLET
- TRINTELLIX 20 MG TABLET
- TRINTELLIX 5 MG TABLET
- VIIBRYD 10 MG (7)-20 MG (23) TABLETS IN A DOSE PACK
- VIIBRYD 10 MG TABLET
- VIIBRYD 20 MG TABLET
- VIIBRYD 40 MG TABLET

Details

Criteria	Step Therapy requires trial of one of the following generic SSRI's in previous 120 days: escitalopram, sertraline, fluoxetine, citalopram, paroxetine, Paxil oral solution, or fluvoxamine. If request is for duloxetine, step not required for diabetic peripheral neuropathy, fibromyalgia, or chronic musculoskeletal pain.
-----------------	--

ARICEPT 23_NVT 2015

Products Affected

Step 2:

- *donepezil 10 mg disintegrating tablet*
- *donepezil 5 mg disintegrating tablet*

Details

Criteria	Step Therapy requires trial of regular donepezil 5 mg or 10mg oral tablets in previous 120 days.
-----------------	--

DEXILANT_2019

Products Affected

Step 2:

- DEXILANT 30 MG CAPSULE, DELAYED RELEASE
- DEXILANT 60 MG CAPSULE, DELAYED RELEASE

Details

Criteria	
	Step therapy requires trial of lansoprazole in the previous 120 days.

DPP4

Products Affected

Step 2:

- JANUMET 50 MG-1,000 MG TABLET
- JANUMET 50 MG-500 MG TABLET
- JANUMET XR 100 MG-1,000 MG TABLET,EXTENDED RELEASE
- JANUMET XR 50 MG-1,000 MG TABLET,EXTENDED RELEASE
- JANUMET XR 50 MG-500 MG TABLET,EXTENDED RELEASE
- JANUVIA 100 MG TABLET
- JANUVIA 25 MG TABLET
- JANUVIA 50 MG TABLET

Step 3:

- KOMBIGLYZE XR 2.5 MG-1,000 MG TABLET,EXTENDED RELEASE
- KOMBIGLYZE XR 5 MG-500 MG TABLET,EXTENDED RELEASE
- KOMBIGLYZE XR 5 MG-1,000 MG TABLET,EXTENDED RELEASE
- ONGLYZA 2.5 MG TABLET
- ONGLYZA 5 MG TABLET

Details

Criteria	Step Therapy requires trial of Metformin for Januvia, Janumet, or Janumet XR in the past 120 days. Trial of both Metformin AND Janumet, Janumet XR, OR Januvia required for Onglyza or Kombiglyze XR in the past 120 days.
-----------------	--

DRY EYE OTC (CCHP 2018)

Products Affected

Step 2:

- RESTASIS 0.05 % EYE DROPS IN A DROPPERETTE

Details

Criteria	
	Step Therapy requires trial of OTC artificial tears.

GLP1

Products Affected

Step 2:

- OZEMPIC 0.25 MG OR 0.5 MG (2 MG/1.5 ML) SUBCUTANEOUS PEN INJECTOR
- OZEMPIC 1 MG/DOSE (2 MG/1.5 ML) SUBCUTANEOUS PEN INJECTOR
- TRULICITY 0.75 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR
- TRULICITY 1.5 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR
- VICTOZA 3-PAK 0.6 MG/0.1 ML (18 MG/3 ML) SUBCUTANEOUS PEN INJECTOR

Details

Criteria
Step Therapy requires trial of METFORMIN in the past 120 days.

LAMA/LABA

Products Affected

Step 2:

- STIOLTO RESPIMAT 2.5 MCG-2.5 MCG/ACTUATION SOLUTION FOR INHALATION

Details

Criteria	Step Therapy requires trial of ANORO.
-----------------	---------------------------------------

OPHTHALMIC ANTI-INFECTIVES_NVT 2015

Products Affected

Step 2:

- BESIVANCE 0.6 % EYE DROPS,SUSPENSION
- *gatifloxacin 0.5 % eye drops*

Details

Criteria	Step Therapy requires trial of one of the following ciprofloxacin, levofloxacin, or ofloxacinin previous 120 days.
-----------------	--

PANCREATIC ENZYMES_NVT 2015

Products Affected

Step 2:

- PANCREAZE 10,500 UNIT-35,500 UNIT-61,500 UNIT CAPSULE,DELAYED RELEASE
- PANCREAZE 16,800 UNIT-56,800 UNIT-98,400 UNIT CAPSULE,DELAYED RELEASE
- PANCREAZE 2,600 UNIT-6,200 UNIT-10,850 UNIT CAPSULE,DELAYED RELEASE
- PANCREAZE 21,000 UNIT-54,700 UNIT-83,900 UNIT CAPSULE,DELAYED RELEASE
- PANCREAZE 4,200 UNIT-14,200 UNIT-24,600 UNIT CAPSULE,DELAYED RELEASE

Details

Criteria
Step Therapy requires trial of CREON in previous 120 days.

POLYETHYLENE GLYCOL

Products Affected

Step 2:

- LINZESS 145 MCG CAPSULE
- LINZESS 290 MCG CAPSULE
- LINZESS 72 MCG CAPSULE
- MOVANTIK 12.5 MG TABLET
- MOVANTIK 25 MG TABLET
- RELISTOR 12 MG/0.6 ML
SUBCUTANEOUS SOLUTION
- RELISTOR 12 MG/0.6 ML
SUBCUTANEOUS SYRINGE
- RELISTOR 8 MG/0.4 ML
SUBCUTANEOUS SYRINGE

Details

Criteria	Step Therapy requires trial of OTC polyethylene glycol in the past 120 days.
-----------------	--

SGLT2

Products Affected

Step 2:

- INVOKAMET 150 MG-1,000 MG TABLET
- INVOKAMET 150 MG-500 MG TABLET
- INVOKAMET 50 MG-1,000 MG TABLET
- INVOKAMET 50 MG-500 MG TABLET
- INVOKAMET XR 150 MG-1,000 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 150 MG-500 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 50 MG-1,000 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 50 MG-500 MG TABLET, EXTENDED RELEASE
- INVOKANA 100 MG TABLET
- INVOKANA 300 MG TABLET
- JARDIANCE 10 MG TABLET
- JARDIANCE 25 MG TABLET
- SYNJARDY 12.5 MG-1,000 MG TABLET
- SYNJARDY 12.5 MG-500 MG TABLET
- SYNJARDY 5 MG-1,000 MG TABLET
- SYNJARDY 5 MG-500 MG TABLET
- SYNJARDY XR 10 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 12.5 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 25 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE

Details

Criteria	
	Step Therapy requires trial of METFORMIN in previous 120days.

ST_RIVASTIGMINE_2019

Products Affected

Step 2:

- *rivastigmine 13.3 mg/24 hour transdermal patch*
- *rivastigmine 9.5 mg/24 hour transdermal patch*
- *rivastigmine 4.6 mg/24 hour transdermal patch*

Details

Criteria	
	Step Therapy requires trial of rivastigmine tablets in past 120 days.

ST_SMOKINGCESS_2019

Products Affected

Step 2:

- *bupropion hcl 150 mg tablet, 12 hr sustained-release(smoking deterrent)*

Details

Criteria
Step therapy requires trial of Nicoderm patches in previous 120 days.

ULORIC_NVT 2015

Products Affected

Step 2:

- *febuxostat 40 mg tablet*
- *febuxostat 80 mg tablet*
- ULORIC 40 MG TABLET
- ULORIC 80 MG TABLET

Details

Criteria
Step Therapy requires trial of allopurinol in previous 120 days.

ZADITOR OTC (CCHP2017)

Products Affected

Step 2:

- *olopatadine 0.1 % eye drops*

Step 3:

- *olopatadine 0.2 % eye drops*
- PAZEO 0.7 % EYE DROPS

Details

Criteria	Step Therapy requires trial of OTC zaditor/ketotifen for olopatadine ophth soln. Trial of olopatadine 1 mg/ml ophth soln required for olopatadine 2 mg/ml and PAZEO
-----------------	---

2020 Chinese Community Health Plan Senior Select Program (HMO SNP)

Step Therapy Criteria
Updated 3/2020

INDEX

A

acyclovir 5 % topical ointment.....1
ALPHAGAN P 0.1 % EYE DROPS2

B

BESIVANCE 0.6 % EYE
DROPS,SUSPENSION10
bupropion hcl 150 mg tablet,12 hr sustained-
release(smoking deterrent)15

D

DESVENLAFAXINE ER 100 MG
TABLET,EXTENDED RELEASE 24 HR
.....3

DESVENLAFAXINE ER 50 MG
TABLET,EXTENDED RELEASE 24 HR
.....3

DESVENLAFAXINE FUMARATE ER 100
MG TABLET, EXTENDED RELEASE
24 HR.....3

DESVENLAFAXINE FUMARATE ER 50
MG TABLET, EXTENDED RELEASE
24 HR.....3

DEXILANT 30 MG CAPSULE,
DELAYED RELEASE.....5

DEXILANT 60 MG CAPSULE,
DELAYED RELEASE.....5

donepezil 10 mg disintegrating tablet.....4

donepezil 5 mg disintegrating tablet.....4

duloxetine 40 mg capsule,delayered release...3

E

EMSAM 12 MG/24 HR TRANSDERMAL
24 HOUR PATCH.....3

EMSAM 6 MG/24 HR TRANSDERMAL
24 HOUR PATCH.....3

EMSAM 9 MG/24 HR TRANSDERMAL
24 HOUR PATCH.....3

F

febuxostat 40 mg tablet16

febuxostat 80 mg tablet16

FETZIMA 120 MG
CAPSULE,EXTENDED RELEASE3

FETZIMA 20 MG (2)-40 MG (26)
CAPSULE,EXTENDED RELEASE,24
HR,DOSE PACK3

FETZIMA 20 MG CAPSULE,EXTENDED
RELEASE.....3

FETZIMA 40 MG CAPSULE,EXTENDED
RELEASE.....3

FETZIMA 80 MG CAPSULE,EXTENDED
RELEASE.....3

fluvoxamine er 100 mg capsule,extended
release 24 hr.....3

fluvoxamine er 150 mg capsule,extended
release 24 hr.....3

G

gatifloxacin 0.5 % eye drops10

I

INVOKAMET 150 MG-1,000 MG
TABLET13

INVOKAMET 150 MG-500 MG TABLET
.....13

INVOKAMET 50 MG-1,000 MG TABLET
.....13

INVOKAMET 50 MG-500 MG TABLET13

INVOKAMET XR 150 MG-1,000 MG
TABLET, EXTENDED RELEASE13

INVOKAMET XR 150 MG-500 MG
TABLET, EXTENDED RELEASE13

INVOKAMET XR 50 MG-1,000 MG
TABLET, EXTENDED RELEASE13

INVOKAMET XR 50 MG-500 MG
TABLET, EXTENDED RELEASE13

INVOKANA 100 MG TABLET13

INVOKANA 300 MG TABLET13

J

JANUMET 50 MG-1,000 MG TABLET6

JANUMET 50 MG-500 MG TABLET6

JANUMET XR 100 MG-1,000 MG
TABLET,EXTENDED RELEASE6

JANUMET XR 50 MG-1,000 MG
TABLET,EXTENDED RELEASE6

JANUMET XR 50 MG-500 MG
TABLET,EXTENDED RELEASE6

2020 Chinese Community Health Plan Senior Select Program (HMO SNP)

Step Therapy Criteria
Updated 3/2020

JANUVIA 100 MG TABLET	6	PANCREAZE 4,200 UNIT-14,200 UNIT- 24,600 UNIT CAPSULE,DELAYED RELEASE.....	11
JANUVIA 25 MG TABLET	6	PAZEO 0.7 % EYE DROPS	17
JANUVIA 50 MG TABLET	6	R	
JARDIANCE 10 MG TABLET	13	RELISTOR 12 MG/0.6 ML SUBCUTANEOUS SOLUTION	12
JARDIANCE 25 MG TABLET	13	RELISTOR 12 MG/0.6 ML SUBCUTANEOUS SYRINGE.....	12
K		RELISTOR 8 MG/0.4 ML SUBCUTANEOUS SYRINGE.....	12
KOMBIGLYZE XR 2.5 MG-1,000 MG TABLET,EXTENDED RELEASE	6	RESTASIS 0.05 % EYE DROPS IN A DROPPERETTE	7
KOMBIGLYZE XR 5 MG-1,000 MG TABLET,EXTENDED RELEASE	6	rivastigmine 13.3 mg/24 hour transdermal patch	14
KOMBIGLYZE XR 5 MG-500 MG TABLET,EXTENDED RELEASE	6	rivastigmine 4.6 mg/24 hour transdermal patch	14
L		rivastigmine 9.5 mg/24 hour transdermal patch	14
LINZESS 145 MCG CAPSULE	12	S	
LINZESS 290 MCG CAPSULE	12	STIOLTO RESPIMAT 2.5 MCG-2.5 MCG/ACTUATION SOLUTION FOR INHALATION	9
LINZESS 72 MCG CAPSULE	12	SYNJARDY 12.5 MG-1,000 MG TABLET	13
M		SYNJARDY 12.5 MG-500 MG TABLET	13
MARPLAN 10 MG TABLET	3	SYNJARDY 5 MG-1,000 MG TABLET..	13
MOVANTIK 12.5 MG TABLET.....	12	SYNJARDY 5 MG-500 MG TABLET.....	13
MOVANTIK 25 MG TABLET.....	12	SYNJARDY XR 10 MG-1,000 MG TABLET, EXTENDED RELEASE	13
O		SYNJARDY XR 12.5 MG-1,000 MG TABLET, EXTENDED RELEASE	13
olopatadine 0.1 % eye drops.....	17	SYNJARDY XR 25 MG-1,000 MG TABLET, EXTENDED RELEASE	13
olopatadine 0.2 % eye drops.....	17	SYNJARDY XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE	13
ONGLYZA 2.5 MG TABLET	6	T	
ONGLYZA 5 MG TABLET	6	TRINTELLIX 10 MG TABLET	3
OZEMPIC 0.25 MG OR 0.5 MG (2 MG/1.5 ML) SUBCUTANEOUS PEN INJECTOR	8	TRINTELLIX 20 MG TABLET	3
OZEMPIC 1 MG/DOSE (2 MG/1.5 ML) SUBCUTANEOUS PEN INJECTOR.....	8	TRINTELLIX 5 MG TABLET	3
P		TRULICITY 0.75 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR.....	8
PANCREAZE 10,500 UNIT-35,500 UNIT- 61,500 UNIT CAPSULE,DELAYED RELEASE.....	11	TRULICITY 1.5 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR.....	8
PANCREAZE 16,800 UNIT-56,800 UNIT- 98,400 UNIT CAPSULE,DELAYED RELEASE.....	11		
PANCREAZE 2,600 UNIT-6,200 UNIT- 10,850 UNIT CAPSULE,DELAYED RELEASE.....	11		
PANCREAZE 21,000 UNIT-54,700 UNIT- 83,900 UNIT CAPSULE,DELAYED RELEASE.....	11		

2020 Chinese Community Health Plan Senior Select Program (HMO SNP)

Step Therapy Criteria
Updated 3/2020

U

ULORIC 40 MG TABLET16
ULORIC 80 MG TABLET16

V

VICTOZA 3-PAK 0.6 MG/0.1 ML (18
MG/3 ML) SUBCUTANEOUS PEN
INJECTOR8

VIIBRYD 10 MG (7)-20 MG (23)

TABLETS IN A DOSE PACK3
VIIBRYD 10 MG TABLET.....3
VIIBRYD 20 MG TABLET.....3
VIIBRYD 40 MG TABLET.....3